Eloralintide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Eloralintide is an investigational long-acting amylin receptor agonist being studied for weight loss, alone and in combination with tirzepatide. The weight-loss effect is well supported, but preferential fat loss, GI tolerability, and GLP-1 synergy claims rest on weak evidence. Nausea affects up to two-thirds of patients at higher doses, and safety data run only to 48 weeks, with none in pregnancy or children. It is not FDA-approved.
Read Full recordStudied uses & evidence
Studied uses(6)
Significant dose-dependent weight loss
High48-week Phase 2 RCT showed dose-dependent weight loss, up to about 20%.
Preferential fat mass reduction
LowA human Phase 2 DXA substudy found that most lost mass was fat. It did not establish the 80–91% preclinical figure or superiority over other treatments.
Favorable GI tolerability
LowPhase 1 data suggested mild GI effects, but Phase 2 nausea reached up to 64%.
Evidence limits
- Evidence Level
- Phase 2 (Lancet RCT, n=263)
Phase 1 (n=48 SAD, n=100 MAD) and Phase 2 (n=263, 48-week RCT published in The Lancet) demonstrate dose-dependent weight loss up to 20% with favorable tolerability. Phase 3 ENLIGHTEN program initiated late 2025 across 171 global sites.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteNo approved eloralintide contraindication list or boxed warning exists. Eloralintide is a selective amylin agonist; an established GLP-1 thyroid-tumor class warning should not be assigned to it. Trial eligibility must follow the relevant protocol.
History of pancreatitis
HighA history of pancreatitis was an exclusion criterion in the Phase 2 trial. This is a trial precaution, not an established incretin-class requirement for eloralintide.
General cautions
Pregnancy
AbsoluteInvestigational — no reproductive safety data.
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Nausea: dose-dependent, from 11% at the lowest to 64% at the highest Phase 2 dose, vs 14% placebo
HighFatigue: reported in 0-46% of participants across dose groups vs 12% placebo
ModerateDecreased appetite: 19% in Phase 1 MAD study
LowHeadache: 12% in Phase 1 MAD study
LowGI effects: diarrhea (10%), vomiting (4%) in Phase 1
ModerateLong-term safety unknown — only 48-week data available from Phase 2
HighInjection site reactions possible (subcutaneous administration)
LowContraindication data not yet fully established (investigational drug)
HighNot studied in pregnancy, lactation, or pediatric populations
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.